Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.38 |
| ▸ | PTGER2 | P43116 | 6/20 | 0.38 |
| ▸ | PTGER3 | P43115 | 6/20 | 0.38 |
| ▸ | PTGER1 | P34995 | 4/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.35 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6072057 | 1.00 | KDM4E (0.41) | KDM4ELMNAPTGER4PTGER2PTGER3 | |
| Hydrochloric Acid SCHEMBL6072692 | 0.99 | KDM4E (0.40) | KDM4ELMNAPTGER4PTGER2PTGER3 | |
| Hydrochloric Acid SCHEMBL6072702 | 0.99 | KDM4E (0.40) | KDM4ELMNAPTGER4PTGER2PTGER3 | |
| SCHEMBL6072339 | 0.90 | KDM4E (0.36) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6072332 | 0.90 | KDM4E (0.36) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6071868 | 0.88 | KDM4E (0.37) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6071869 | 0.88 | KDM4E (0.37) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6071874 | 0.88 | KDM4E (0.37) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6071864 | 0.88 | KDM4E (0.37) | KDM4EGLAALDH1A1GAA | |
| SCHEMBL6072731 | 0.87 | KDM4E (0.38) | KDM4EGLAALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | KDM4E 358/4885LMNA 2455/4885PTGER4 446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.